35
Participants
Start Date
January 30, 2024
Primary Completion Date
October 4, 2028
Study Completion Date
April 2, 2032
CSL222 (AAV5-hFIXco-Padua)
Administered as a single IV infusion.
RECRUITING
Tri-Service General Hospital - 15800012, Taipei
RECRUITING
Changhua Christian Hospital (CCH) - 15800009, Chang-hua
RECRUITING
Royal Prince Alfred Hospital - 03600044, Camperdown
RECRUITING
Haemophilia Comprehensive Care Centre - 71000001, Johannesburg
RECRUITING
The Alfred Hospital - 03600043, Melbourne
RECRUITING
Centro de Investigacion Clinica GRAMEL S.C. - 48400003, Mexico City
RECRUITING
Severance Hospital, Yonsei University Health System - 41000013, Seoul
RECRUITING
Royal Brisbane Hospital - 03600045, Herston
RECRUITING
King Faisal Specialist Hospital and Research Center - 68200001, Riyadh
RECRUITING
Gaziantep University Sahinbey Research and Practice Hospital - 79200004, Gaziantep
RECRUITING
Ege University Medical Faculty - 79200002, Bornova
RECRUITING
Taichung Veterans General Hospital - 15800007, Taichung
RECRUITING
Kyungpook National University Hospital - 41000014, Daegu
RECRUITING
University of Michigan - 84000285, Ann Arbor
RECRUITING
Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH) - 15800011, Kaohsiung City
RECRUITING
University of California, San Diego (UCSD) - 84000460, San Diego
RECRUITING
National University Hospital - 70200002, Singapore
RECRUITING
Queen Mary Hospital - 34400001, Hong Kong
RECRUITING
Prince of Wales Hospital Chinese University of Hong Kong - 34400002, Shatin
RECRUITING
Sheba Medical Center - 37600004, Tel Litwinsky
RECRUITING
McMaster University - Hamilton - 12400017, Hamilton
RECRUITING
Kyung Hee University Hospital at Gangdong - 41000015, Seoul
RECRUITING
Özel Acibadem Adana Hastanesi - 79200003, Seyhan
Lead Sponsor
CSL Behring
INDUSTRY